Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831
- Citation:
- Cancer vol 119 (15) 2675-2682
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- A. Moreno-Aspitia D. W. Hillman S. H. Dyar K. S. Tenner J. Gralow P. A. Kaufman N. E. Davidson J. M. Lafky M. M. Reinholz W. L. Lingle L. A. Kutteh W. P. Carney A. C. Dueck E. A. Perez
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Article